CF PharmTech, Inc. (H-share) disclosed a share buyback executed on 04 May 2026. Key details are as follows:

• Transaction size and price: 5,500 H shares were repurchased on the Hong Kong Stock Exchange at prices between HKD 21.98 and HKD 22.78, for a volume-weighted average of HKD 22.45 per share. The aggregate consideration was HKD 0.12 million.

• Impact on share capital: The repurchase represents 0.0018% of the company’s 301.56 million issued shares (excluding treasury shares) outstanding before the transaction. Post-transaction, issued shares decreased to 301.55 million, while treasury shares rose to 670,500, keeping total issued shares unchanged at 302.22 million.

• Mandate utilisation: Since the current buyback authority was approved on 16 December 2025, CF PharmTech has repurchased 670,500 shares, equivalent to 0.22% of the issued share base at the mandate date. The company is authorised to repurchase up to 30.22 million shares under this mandate.

• Moratorium: Following the 04 May transaction, the company is restricted from issuing new shares or disposing of treasury shares until 03 June 2026, in accordance with Hong Kong Listing Rules.

All repurchases were conducted in compliance with the Listing Rules and relevant regulatory requirements, according to the company’s filing signed by Executive Director and Joint Company Secretary Zhu Yuyu on 04 May 2026.